← All trials
NCT06475508
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 13, 2023
- Primary completion
- Jan 5, 2024
- Completion date
- Jun 11, 2024
- First posted
- Jun 26, 2024
- Last posted
- Jul 3, 2024
- Enrollment
- 465
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AO GENERIUMLead sponsor
- AO GENERIUMOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.